Ascendis Pharma tumbles on Novo Nordisk collab termination

Novo Nordisk A/S

15/09/2026 16:11

** Shares of Ascendis Pharma ASND.O fall 13.3% to $229.79
** ASND said late on Monday it had ended its partnership with Danish drugmaker Novo Nordisk NOVOb.CO 
** ASND regained all exclusive rights to its TransCon technology for metabolic and cardiovascular diseases
** "We see the repo as a clear positive and ultimately see better potential for value creation with the targets back in ASND’s hands given what had become slow progress moving TransCon Sema into the clinic, which still has yet to happen nearly two years after the collab was announced," J.P. Morgan analysts says
** ASND partnered with Novo Nordisk in 2024 to develop long-acting obesity and diabetes treatments in a deal worth up to $285 mln
** Both companies ended all ongoing financial obligations to each other
** Separately, ASND announced a plan to buy back up to $400 mln of its own shares
** Including session's move, ASND up 8.8% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))